25
Participants
Start Date
June 2, 2019
Primary Completion Date
September 27, 2021
Study Completion Date
September 27, 2021
Abatacept
Abatacept for reconstitution and dilution prior to intravenous (IV) administration. Each single-use vial of Abatacept for injection provides 250-mg Abatacept, maltose (500 mg), monobasic sodium phosphate (17.2 mg), and sodium chloride (14.6 mg) for administration.
DMARDs
Patients will receive methotrexate or remain on pre-existing conventional synthetic disease-modifying anti-rheumatic drug (DMARD) if already prescribed.
Dartmouth-Hitchcock Medical Center, Lebanon
Collaborators (1)
Dartmouth-Hitchcock Medical Center
OTHER
Bristol-Myers Squibb
INDUSTRY
NYU Langone Health
OTHER